TA
PTLA

Tamarack Advisers’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Tamarack Advisers’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,500
Closed -$175K – 27
2018
Q4 		$175K Buy
+3,500
New +$72K 0.07% 21

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Tamarack Advisers's PTLA Position: Q1 2020 in Review

Tamarack Advisers sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 595,000 shares — an estimated $14.3M sold.

Tamarack Advisers first reported a position in PTLA in Q4 2018 and held it in 5 quarters. The position peaked at $26.8M in Q3 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Tamarack Advisers reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Tamarack Advisers sold 595,000 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $14.3M.
  • Tamarack Advisers first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
  • Tamarack Advisers's Portola Pharmaceuticals, Inc. position peaked at $26.8M in Q3 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Tamarack Advisers's 13F filing for Q1 2020, filed 14 May 2020.